Report Detail
Global Precision Cancer Therapeutics Market Growth (Status and Outlook) 2023-2029
- RnM4510680 |
- 15 February, 2023 |
- Global |
- 121 Pages |
- LPI(LP Information) |
- Medical Industry
The global Precision Cancer Therapeutics market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Precision Cancer Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Precision Cancer Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Precision Cancer Therapeutics is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Precision Cancer Therapeutics players cover AbbVie, Astellas Pharma U.S., Inc, AstraZeneca PLC, Bayer AG, Bristol-Myers Squibb Company, Clovis Oncology, Inc., Dendreon Pharmaceuticals LLC, Eli Lilly & Company and EMD Serono, Inc. (Merck KgaA), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
LPI (LP Information)' newest research report, the “Precision Cancer Therapeutics Industry Forecast” looks at past sales and reviews total world Precision Cancer Therapeutics sales in 2022, providing a comprehensive analysis by region and market sector of projected Precision Cancer Therapeutics sales for 2023 through 2029. With Precision Cancer Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Precision Cancer Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Precision Cancer Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Precision Cancer Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Precision Cancer Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Precision Cancer Therapeutics and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Precision Cancer Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Precision Cancer Therapeutics market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Monoclonal Antibodies
Kinase Inhibitors
Angiogenesis Inhibitors
Proteasome Inhibitors
CAR-T Therapies
Other Precision Therapies
Segmentation by application
Breast Cancer
Lung Cancer
Prostate Cancer
Colon and Rectal Cancer
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Astellas Pharma U.S., Inc
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Clovis Oncology, Inc.
Dendreon Pharmaceuticals LLC
Eli Lilly & Company
EMD Serono, Inc. (Merck KgaA)
Eisai Co., Ltd.
Exelixis, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Otsuka Holdings Co., Ltd.
Pfizer, Inc.
Puma Biotechnology, Inc.
Roche (F. Hoffman-La Roche, Ltd.)
Sanofi/Genzyme
Seagen Inc.
Takeda
1 Scope of the Report
- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats
2 Executive Summary
- 2.1 World Market Overview
- 2.1.1 Global Precision Cancer Therapeutics Market Size 2018-2029
- 2.1.2 Precision Cancer Therapeutics Market Size CAGR by Region 2018 VS 2022 VS 2029
- 2.2 Precision Cancer Therapeutics Segment by Type
- 2.2.1 Monoclonal Antibodies
- 2.2.2 Kinase Inhibitors
- 2.2.3 Angiogenesis Inhibitors
- 2.2.4 Proteasome Inhibitors
- 2.2.5 CAR-T Therapies
- 2.2.6 Other Precision Therapies
- 2.3 Precision Cancer Therapeutics Market Size by Type
- 2.3.1 Precision Cancer Therapeutics Market Size CAGR by Type (2018 VS 2022 VS 2029)
- 2.3.2 Global Precision Cancer Therapeutics Market Size Market Share by Type (2018-2023)
- 2.4 Precision Cancer Therapeutics Segment by Application
- 2.4.1 Breast Cancer
- 2.4.2 Lung Cancer
- 2.4.3 Prostate Cancer
- 2.4.4 Colon and Rectal Cancer
- 2.4.5 Others
- 2.5 Precision Cancer Therapeutics Market Size by Application
- 2.5.1 Precision Cancer Therapeutics Market Size CAGR by Application (2018 VS 2022 VS 2029)
- 2.5.2 Global Precision Cancer Therapeutics Market Size Market Share by Application (2018-2023)
3 Precision Cancer Therapeutics Market Size by Player
- 3.1 Precision Cancer Therapeutics Market Size Market Share by Players
- 3.1.1 Global Precision Cancer Therapeutics Revenue by Players (2018-2023)
- 3.1.2 Global Precision Cancer Therapeutics Revenue Market Share by Players (2018-2023)
- 3.2 Global Precision Cancer Therapeutics Key Players Head office and Products Offered
- 3.3 Market Concentration Rate Analysis
- 3.3.1 Competition Landscape Analysis
- 3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
- 3.4 New Products and Potential Entrants
- 3.5 Mergers & Acquisitions, Expansion
4 Precision Cancer Therapeutics by Regions
- 4.1 Precision Cancer Therapeutics Market Size by Regions (2018-2023)
- 4.2 Americas Precision Cancer Therapeutics Market Size Growth (2018-2023)
- 4.3 APAC Precision Cancer Therapeutics Market Size Growth (2018-2023)
- 4.4 Europe Precision Cancer Therapeutics Market Size Growth (2018-2023)
- 4.5 Middle East & Africa Precision Cancer Therapeutics Market Size Growth (2018-2023)
5 Americas
- 5.1 Americas Precision Cancer Therapeutics Market Size by Country (2018-2023)
- 5.2 Americas Precision Cancer Therapeutics Market Size by Type (2018-2023)
- 5.3 Americas Precision Cancer Therapeutics Market Size by Application (2018-2023)
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil
6 APAC
- 6.1 APAC Precision Cancer Therapeutics Market Size by Region (2018-2023)
- 6.2 APAC Precision Cancer Therapeutics Market Size by Type (2018-2023)
- 6.3 APAC Precision Cancer Therapeutics Market Size by Application (2018-2023)
- 6.4 China
- 6.5 Japan
- 6.6 Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
7 Europe
- 7.1 Europe Precision Cancer Therapeutics by Country (2018-2023)
- 7.2 Europe Precision Cancer Therapeutics Market Size by Type (2018-2023)
- 7.3 Europe Precision Cancer Therapeutics Market Size by Application (2018-2023)
- 7.4 Germany
- 7.5 France
- 7.6 UK
- 7.7 Italy
- 7.8 Russia
8 Middle East & Africa
- 8.1 Middle East & Africa Precision Cancer Therapeutics by Region (2018-2023)
- 8.2 Middle East & Africa Precision Cancer Therapeutics Market Size by Type (2018-2023)
- 8.3 Middle East & Africa Precision Cancer Therapeutics Market Size by Application (2018-2023)
- 8.4 Egypt
- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries
9 Market Drivers, Challenges and Trends
- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends
10 Global Precision Cancer Therapeutics Market Forecast
- 10.1 Global Precision Cancer Therapeutics Forecast by Regions (2024-2029)
- 10.1.1 Global Precision Cancer Therapeutics Forecast by Regions (2024-2029)
- 10.1.2 Americas Precision Cancer Therapeutics Forecast
- 10.1.3 APAC Precision Cancer Therapeutics Forecast
- 10.1.4 Europe Precision Cancer Therapeutics Forecast
- 10.1.5 Middle East & Africa Precision Cancer Therapeutics Forecast
- 10.2 Americas Precision Cancer Therapeutics Forecast by Country (2024-2029)
- 10.2.1 United States Precision Cancer Therapeutics Market Forecast
- 10.2.2 Canada Precision Cancer Therapeutics Market Forecast
- 10.2.3 Mexico Precision Cancer Therapeutics Market Forecast
- 10.2.4 Brazil Precision Cancer Therapeutics Market Forecast
- 10.3 APAC Precision Cancer Therapeutics Forecast by Region (2024-2029)
- 10.3.1 China Precision Cancer Therapeutics Market Forecast
- 10.3.2 Japan Precision Cancer Therapeutics Market Forecast
- 10.3.3 Korea Precision Cancer Therapeutics Market Forecast
- 10.3.4 Southeast Asia Precision Cancer Therapeutics Market Forecast
- 10.3.5 India Precision Cancer Therapeutics Market Forecast
- 10.3.6 Australia Precision Cancer Therapeutics Market Forecast
- 10.4 Europe Precision Cancer Therapeutics Forecast by Country (2024-2029)
- 10.4.1 Germany Precision Cancer Therapeutics Market Forecast
- 10.4.2 France Precision Cancer Therapeutics Market Forecast
- 10.4.3 UK Precision Cancer Therapeutics Market Forecast
- 10.4.4 Italy Precision Cancer Therapeutics Market Forecast
- 10.4.5 Russia Precision Cancer Therapeutics Market Forecast
- 10.5 Middle East & Africa Precision Cancer Therapeutics Forecast by Region (2024-2029)
- 10.5.1 Egypt Precision Cancer Therapeutics Market Forecast
- 10.5.2 South Africa Precision Cancer Therapeutics Market Forecast
- 10.5.3 Israel Precision Cancer Therapeutics Market Forecast
- 10.5.4 Turkey Precision Cancer Therapeutics Market Forecast
- 10.5.5 GCC Countries Precision Cancer Therapeutics Market Forecast
- 10.6 Global Precision Cancer Therapeutics Forecast by Type (2024-2029)
- 10.7 Global Precision Cancer Therapeutics Forecast by Application (2024-2029)
11 Key Players Analysis
- 11.1 AbbVie
- 11.1.1 AbbVie Company Information
- 11.1.2 AbbVie Precision Cancer Therapeutics Product Offered
- 11.1.3 AbbVie Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.1.4 AbbVie Main Business Overview
- 11.1.5 AbbVie Latest Developments
- 11.2 Astellas Pharma U.S., Inc
- 11.2.1 Astellas Pharma U.S., Inc Company Information
- 11.2.2 Astellas Pharma U.S., Inc Precision Cancer Therapeutics Product Offered
- 11.2.3 Astellas Pharma U.S., Inc Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.2.4 Astellas Pharma U.S., Inc Main Business Overview
- 11.2.5 Astellas Pharma U.S., Inc Latest Developments
- 11.3 AstraZeneca PLC
- 11.3.1 AstraZeneca PLC Company Information
- 11.3.2 AstraZeneca PLC Precision Cancer Therapeutics Product Offered
- 11.3.3 AstraZeneca PLC Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.3.4 AstraZeneca PLC Main Business Overview
- 11.3.5 AstraZeneca PLC Latest Developments
- 11.4 Bayer AG
- 11.4.1 Bayer AG Company Information
- 11.4.2 Bayer AG Precision Cancer Therapeutics Product Offered
- 11.4.3 Bayer AG Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.4.4 Bayer AG Main Business Overview
- 11.4.5 Bayer AG Latest Developments
- 11.5 Bristol-Myers Squibb Company
- 11.5.1 Bristol-Myers Squibb Company Company Information
- 11.5.2 Bristol-Myers Squibb Company Precision Cancer Therapeutics Product Offered
- 11.5.3 Bristol-Myers Squibb Company Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.5.4 Bristol-Myers Squibb Company Main Business Overview
- 11.5.5 Bristol-Myers Squibb Company Latest Developments
- 11.6 Clovis Oncology, Inc.
- 11.6.1 Clovis Oncology, Inc. Company Information
- 11.6.2 Clovis Oncology, Inc. Precision Cancer Therapeutics Product Offered
- 11.6.3 Clovis Oncology, Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.6.4 Clovis Oncology, Inc. Main Business Overview
- 11.6.5 Clovis Oncology, Inc. Latest Developments
- 11.7 Dendreon Pharmaceuticals LLC
- 11.7.1 Dendreon Pharmaceuticals LLC Company Information
- 11.7.2 Dendreon Pharmaceuticals LLC Precision Cancer Therapeutics Product Offered
- 11.7.3 Dendreon Pharmaceuticals LLC Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.7.4 Dendreon Pharmaceuticals LLC Main Business Overview
- 11.7.5 Dendreon Pharmaceuticals LLC Latest Developments
- 11.8 Eli Lilly & Company
- 11.8.1 Eli Lilly & Company Company Information
- 11.8.2 Eli Lilly & Company Precision Cancer Therapeutics Product Offered
- 11.8.3 Eli Lilly & Company Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.8.4 Eli Lilly & Company Main Business Overview
- 11.8.5 Eli Lilly & Company Latest Developments
- 11.9 EMD Serono, Inc. (Merck KgaA)
- 11.9.1 EMD Serono, Inc. (Merck KgaA) Company Information
- 11.9.2 EMD Serono, Inc. (Merck KgaA) Precision Cancer Therapeutics Product Offered
- 11.9.3 EMD Serono, Inc. (Merck KgaA) Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.9.4 EMD Serono, Inc. (Merck KgaA) Main Business Overview
- 11.9.5 EMD Serono, Inc. (Merck KgaA) Latest Developments
- 11.10 Eisai Co., Ltd.
- 11.10.1 Eisai Co., Ltd. Company Information
- 11.10.2 Eisai Co., Ltd. Precision Cancer Therapeutics Product Offered
- 11.10.3 Eisai Co., Ltd. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.10.4 Eisai Co., Ltd. Main Business Overview
- 11.10.5 Eisai Co., Ltd. Latest Developments
- 11.11 Exelixis, Inc.
- 11.11.1 Exelixis, Inc. Company Information
- 11.11.2 Exelixis, Inc. Precision Cancer Therapeutics Product Offered
- 11.11.3 Exelixis, Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.11.4 Exelixis, Inc. Main Business Overview
- 11.11.5 Exelixis, Inc. Latest Developments
- 11.12 Gilead Sciences, Inc.
- 11.12.1 Gilead Sciences, Inc. Company Information
- 11.12.2 Gilead Sciences, Inc. Precision Cancer Therapeutics Product Offered
- 11.12.3 Gilead Sciences, Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.12.4 Gilead Sciences, Inc. Main Business Overview
- 11.12.5 Gilead Sciences, Inc. Latest Developments
- 11.13 GlaxoSmithKline
- 11.13.1 GlaxoSmithKline Company Information
- 11.13.2 GlaxoSmithKline Precision Cancer Therapeutics Product Offered
- 11.13.3 GlaxoSmithKline Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.13.4 GlaxoSmithKline Main Business Overview
- 11.13.5 GlaxoSmithKline Latest Developments
- 11.14 Johnson & Johnson
- 11.14.1 Johnson & Johnson Company Information
- 11.14.2 Johnson & Johnson Precision Cancer Therapeutics Product Offered
- 11.14.3 Johnson & Johnson Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.14.4 Johnson & Johnson Main Business Overview
- 11.14.5 Johnson & Johnson Latest Developments
- 11.15 Merck & Co., Inc.
- 11.15.1 Merck & Co., Inc. Company Information
- 11.15.2 Merck & Co., Inc. Precision Cancer Therapeutics Product Offered
- 11.15.3 Merck & Co., Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.15.4 Merck & Co., Inc. Main Business Overview
- 11.15.5 Merck & Co., Inc. Latest Developments
- 11.16 Novartis AG
- 11.16.1 Novartis AG Company Information
- 11.16.2 Novartis AG Precision Cancer Therapeutics Product Offered
- 11.16.3 Novartis AG Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.16.4 Novartis AG Main Business Overview
- 11.16.5 Novartis AG Latest Developments
- 11.17 Otsuka Holdings Co., Ltd.
- 11.17.1 Otsuka Holdings Co., Ltd. Company Information
- 11.17.2 Otsuka Holdings Co., Ltd. Precision Cancer Therapeutics Product Offered
- 11.17.3 Otsuka Holdings Co., Ltd. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.17.4 Otsuka Holdings Co., Ltd. Main Business Overview
- 11.17.5 Otsuka Holdings Co., Ltd. Latest Developments
- 11.18 Pfizer, Inc.
- 11.18.1 Pfizer, Inc. Company Information
- 11.18.2 Pfizer, Inc. Precision Cancer Therapeutics Product Offered
- 11.18.3 Pfizer, Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.18.4 Pfizer, Inc. Main Business Overview
- 11.18.5 Pfizer, Inc. Latest Developments
- 11.19 Puma Biotechnology, Inc.
- 11.19.1 Puma Biotechnology, Inc. Company Information
- 11.19.2 Puma Biotechnology, Inc. Precision Cancer Therapeutics Product Offered
- 11.19.3 Puma Biotechnology, Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.19.4 Puma Biotechnology, Inc. Main Business Overview
- 11.19.5 Puma Biotechnology, Inc. Latest Developments
- 11.20 Roche (F. Hoffman-La Roche, Ltd.)
- 11.20.1 Roche (F. Hoffman-La Roche, Ltd.) Company Information
- 11.20.2 Roche (F. Hoffman-La Roche, Ltd.) Precision Cancer Therapeutics Product Offered
- 11.20.3 Roche (F. Hoffman-La Roche, Ltd.) Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.20.4 Roche (F. Hoffman-La Roche, Ltd.) Main Business Overview
- 11.20.5 Roche (F. Hoffman-La Roche, Ltd.) Latest Developments
- 11.21 Sanofi/Genzyme
- 11.21.1 Sanofi/Genzyme Company Information
- 11.21.2 Sanofi/Genzyme Precision Cancer Therapeutics Product Offered
- 11.21.3 Sanofi/Genzyme Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.21.4 Sanofi/Genzyme Main Business Overview
- 11.21.5 Sanofi/Genzyme Latest Developments
- 11.22 Seagen Inc.
- 11.22.1 Seagen Inc. Company Information
- 11.22.2 Seagen Inc. Precision Cancer Therapeutics Product Offered
- 11.22.3 Seagen Inc. Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.22.4 Seagen Inc. Main Business Overview
- 11.22.5 Seagen Inc. Latest Developments
- 11.23 Takeda
- 11.23.1 Takeda Company Information
- 11.23.2 Takeda Precision Cancer Therapeutics Product Offered
- 11.23.3 Takeda Precision Cancer Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
- 11.23.4 Takeda Main Business Overview
- 11.23.5 Takeda Latest Developments
12 Research Findings and Conclusion
Summary:
Get latest Market Research Reports on Precision Cancer Therapeutics. Industry analysis & Market Report on Precision Cancer Therapeutics is a syndicated market report, published as Global Precision Cancer Therapeutics Market Growth (Status and Outlook) 2023-2029. It is complete Research Study and Industry Analysis of Precision Cancer Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
